Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash from Financing Activities (2017 - 2025)

Historic Cash from Financing Activities for Rhythm Pharmaceuticals (RYTM) over the last 9 years, with Q3 2025 value amounting to $189.3 million.

  • Rhythm Pharmaceuticals' Cash from Financing Activities rose 749634.83% to $189.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $259.2 million, marking a year-over-year increase of 6688.81%. This contributed to the annual value of $191.2 million for FY2024, which is 15715.63% up from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Cash from Financing Activities is $189.3 million, which was up 749634.83% from -$889000.0 recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year Cash from Financing Activities high stood at $189.3 million for Q3 2025, and its period low was -$965000.0 during Q2 2023.
  • Over the past 5 years, Rhythm Pharmaceuticals' median Cash from Financing Activities value was $4.2 million (recorded in 2024), while the average stood at $45.6 million.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Cash from Financing Activities surged by 3829322.03% in 2022, and later crashed by 13333.33% in 2023.
  • Quarter analysis of 5 years shows Rhythm Pharmaceuticals' Cash from Financing Activities stood at $100000.0 in 2021, then skyrocketed by 17265.0% to $17.4 million in 2022, then tumbled by 86.05% to $2.4 million in 2023, then skyrocketed by 1481.84% to $38.3 million in 2024, then skyrocketed by 393.9% to $189.3 million in 2025.
  • Its Cash from Financing Activities stands at $189.3 million for Q3 2025, versus -$889000.0 for Q2 2025 and $32.5 million for Q1 2025.